Navigation Links
Signalife Establishes Signalcare Division
Date:2/14/2008

LOS ANGELES, Feb. 14 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has established a division focused on developing, acquiring and/or testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.

From experience gained and relationships developed through the deployment of its award-winning Fidelity 100 Heart Monitor - including extensive utilization of the Fidelity 100 at this year's Super Bowl in Glendale, Arizona -- the Company has already learned significant details regarding the relationship between earlier and more accurate cardiovascular monitoring, on the one hand, and effective cardiovascular treatment-oriented technologies, on the other hand.

Dr. Lowell Harmison, the Company's President and Chief Executive Officer, commented that "more effective heart monitoring can be used to validate or invalidate technologies that, before now, were unable to be properly vetted. Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies."

The Company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Signalife to Deploy Fidelity 100 Heart Monitors for AFL
2. LifeNet Health Establishes The Skin & Wound Allograft Institute
3. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
4. AT&T Establishes New Network Services for Leading Medical Liability Insurer
5. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
6. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
7. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
8. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
9. CIG Corp. Establishes a Medical Advisory Board
10. MM2 Group Establishes New Venture for Sofgel Manufacture in China
11. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology: